Fontanet Bijou
Hematology — Institut Bergonié, France
Fontanet Bijou
LeadR Profile
Hematology
Subspecialties: Oncology - Immunology - Public Health
Main Topics
Publications and Clinical Studies
Organizations
Institut Bergonié -
Publications Synthesis
Source: Pubmed
Number : 108
Citations
Main journals
Best Journals
Breakdown by type
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis. lymphoma, follicular, hematology, lymphoma, rituximab, lenalidomide, therapeutics | Blood | 2026 | 0 |
| Comparative efficacy of zanubrutinib plus obinutuzumab versus last prior treatment in relapsed/refractory follicular lymphoma: growth modulation index analysis from the ROSEWOOD study. lymphoma, follicular, growth, lymphoma, neoplasms, therapeutics | ESMO Open | 2026 | 0 |
| BRAF inhibitor plus rituximab in classical hairy cell leukaemia: A retrospective multicentre real-life study. cells, hematology, rituximab, vemurafenib | Br J Haematol | 2026 | 0 |
| Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma. cells, safety, brentuximab vedotin, lymphoma, b-cell, lymphoma, lymphoma, large b-cell, diffuse, therapeutics, medical oncology, b-lymphocytes | J Clin Oncol Top journal | 2025 | 4 |
| Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma. cells, confidence intervals, progression-free survival, lymphoma, disease progression, rituximab, lymphoma, mantle-cell, medical oncology | J Clin Oncol Top journal | 2025 | 0 |
Clinical Studies 19
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
5 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Determinants of the Response to BTK Degraders (BTKd) in Chronic Lymphocytic Leukemia NCT07099443 — cells, genes, bcl-2, leukemia, lymphocytic, chronic, b-cell, leukemia, leukemia, lymphoid, protein-tyrosine kinases, specimen handling, research, agammaglobulinaemia tyrosine kinase, tyrosine, therapeutics, b-lymphocytes | N/A | Recruiting | 2025 |
| Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients NCT05735834 — lymphoma, solutions, capsules, rituximab, therapeutics | Phase 3 | Active not recruiting | 2024 |
| Study of Mosunetuzumab Plus Lenalidomide Compared to Anti CD20 Anti body Chemotherapy in Follicular Lymphoma FLIPI2 5 NCT06284122 — lymphoma, follicular, safety, prednisone, lymphoma, cyclophosphamide, doxorubicin, drug therapy, rituximab, vincristine, antibodies, monoclonal, lenalidomide, bendamustine hydrochloride, chemotherapy | Phase 3 | Recruiting | 2024 |
| Prognostic Analyses on a Validation Series of Patients With Waldenstr m s Disease NCT05911802 — genes, disease-free survival, progression-free survival, waldenstrom macroglobulinemia, therapeutics, mutation | N/A | Recruiting | 2023 |
| Mosunetuzumab Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma NCT06006117 — cells, creatinine, antibodies, prednisone, lymphoma, b-cell, lymphoma, cyclophosphamide, doxorubicin, lymphoma, b-cell, marginal zone, rituximab, vincristine, lenalidomide, therapeutics, bendamustine hydrochloride, antibodies, bispecific, b-lymphocytes | Phase 3 | Recruiting | 2023 |
LeadR Networks
Main global connection map